atm

FDA Approves New DVT Blood Clot Treatment

Title: FDA Approves New DVT Blood Clot Treatment
Category: Health News
Created: 8/23/2014 11:00:00 AM
Last Editorial Review: 8/25/2014 12:00:00 AM




atm

Sleep Apnea Treatment Helps Seniors, Study Finds

Title: Sleep Apnea Treatment Helps Seniors, Study Finds
Category: Health News
Created: 8/27/2014 12:35:00 PM
Last Editorial Review: 8/28/2014 12:00:00 AM




atm

Impotence Drug Aids Treatment of Rare Lung Disease: Study

Title: Impotence Drug Aids Treatment of Rare Lung Disease: Study
Category: Health News
Created: 8/26/2015 12:00:00 AM
Last Editorial Review: 8/27/2015 12:00:00 AM




atm

Steroid Treatments May Boost Preemies' Risk of Eye Problems

Title: Steroid Treatments May Boost Preemies' Risk of Eye Problems
Category: Health News
Created: 8/19/2016 12:00:00 AM
Last Editorial Review: 8/22/2016 12:00:00 AM




atm

Hopes Dashed for Rare Bone Cancer Treatment

Title: Hopes Dashed for Rare Bone Cancer Treatment
Category: Health News
Created: 8/26/2016 12:00:00 AM
Last Editorial Review: 8/26/2016 12:00:00 AM




atm

Common Treatment for Early Prostate Cancer May Carry Heart Risk

Title: Common Treatment for Early Prostate Cancer May Carry Heart Risk
Category: Health News
Created: 8/25/2017 12:00:00 AM
Last Editorial Review: 8/28/2017 12:00:00 AM




atm

Many U.S. Women Unaware of Fibroid Treatments: Poll

Title: Many U.S. Women Unaware of Fibroid Treatments: Poll
Category: Health News
Created: 8/29/2017 12:00:00 AM
Last Editorial Review: 8/30/2017 12:00:00 AM




atm

Pediatric Treatment Approved for 'Kissing Bug' Disease

Title: Pediatric Treatment Approved for 'Kissing Bug' Disease
Category: Health News
Created: 8/30/2017 12:00:00 AM
Last Editorial Review: 8/31/2017 12:00:00 AM




atm

Two Ebola Patients Who Received Experimental Treatment Have Recovered: Congo Officials

Title: Two Ebola Patients Who Received Experimental Treatment Have Recovered: Congo Officials
Category: Health News
Created: 8/27/2018 12:00:00 AM
Last Editorial Review: 8/27/2018 12:00:00 AM




atm

Ancient Treatment May Help Fight 'Superbugs'

Title: Ancient Treatment May Help Fight 'Superbugs'
Category: Health News
Created: 8/29/2018 12:00:00 AM
Last Editorial Review: 8/30/2018 12:00:00 AM




atm

What Treatments Work Best to Prevent Suicide?

Title: What Treatments Work Best to Prevent Suicide?
Category: Health News
Created: 8/27/2019 12:00:00 AM
Last Editorial Review: 8/27/2019 12:00:00 AM




atm

FDA Approves Wider Use of Plasma as Coronavirus Treatment

Title: FDA Approves Wider Use of Plasma as Coronavirus Treatment
Category: Health News
Created: 8/24/2020 12:00:00 AM
Last Editorial Review: 8/25/2020 12:00:00 AM




atm

AHA News: People With Dementia May Be Less Likely to Receive an Advanced Treatment For Stroke

Title: AHA News: People With Dementia May Be Less Likely to Receive an Advanced Treatment For Stroke
Category: Health News
Created: 8/24/2022 12:00:00 AM
Last Editorial Review: 8/24/2022 12:00:00 AM




atm

Fecal Transplant Treatments Could Transmit Monkeypox, FDA Warns

Title: Fecal Transplant Treatments Could Transmit Monkeypox, FDA Warns
Category: Health News
Created: 8/24/2022 12:00:00 AM
Last Editorial Review: 8/25/2022 12:00:00 AM




atm

New Multiple Sclerosis Treatment Shows Promise in Trial

Title: New Multiple Sclerosis Treatment Shows Promise in Trial
Category: Health News
Created: 8/25/2022 12:00:00 AM
Last Editorial Review: 8/26/2022 12:00:00 AM




atm

Hepatitis C Infection Can Kill, But Less Than a Third of Patients Get Treatment

Title: Hepatitis C Infection Can Kill, But Less Than a Third of Patients Get Treatment
Category: Health News
Created: 8/10/2022 12:00:00 AM
Last Editorial Review: 8/10/2022 12:00:00 AM




atm

Cold, Flu, Allergy Treatments

Title: Cold, Flu, Allergy Treatments
Category: Diseases and Conditions
Created: 9/24/1999 12:00:00 AM
Last Editorial Review: 7/15/2022 12:00:00 AM




atm

Headache Treatment Options

Family medicine physicians often see headache as the chief complaint when meeting patients within their practice. The goal is to try different treatment modalities without having to send the patient to a specialist. Headaches affect different individuals during their lifetime. Before any treatment begins, it is best that one rules out possible causes of the headache, for example, drug interactions or structural cerebrum conditions. Nonpharmacological treatment is recommended first before attempting a stepwise approach to cost-effective pharmacological treatment options. Pharmacological treatment options should include preventive and on-demand options. A family physician has all the resources to assist patients with different types of headaches.




atm

Supporting Evidence For Pulmonary Rehabilitation in the Treatment of Long COVID




atm

The treatment of latent tuberculosis infection in migrants in primary care versus secondary care

Extract

With a disproportionate burden of tuberculosis (TB) amongst migrants in Europe [1], Burman et al. [2] have highlighted the pressing need for alternative approaches to make TB infection (TBI) screening comprehensive and accessible. Across high-income Organisation for Economic Co-operation and development countries, a median of 52% of TB cases occur in foreign-born individuals, who are at their highest risk of developing TB disease within the first 5 years of migration [3]. Molecular epidemiological studies indicate that the majority of these cases occur as a result of TBI reactivation, often acquired overseas [4]. Within the UK, overseas-born migrants have a 14-fold higher TB incidence than UK-born individuals [5]. The World Health Organization therefore recommends that migrants from countries with a high TB burden may be prioritised for TBI screening [6, 7].




atm

Treatment of latent tuberculosis infection in migrants in primary care versus secondary care

Background

Control of latent tuberculosis infection (LTBI) is a priority in the World Health Organization strategy to eliminate TB. Many high-income, low TB incidence countries have prioritised LTBI screening and treatment in recent migrants. We tested whether a novel model of care, based entirely within primary care, was effective and safe compared to secondary care.

Methods

This was a pragmatic cluster-randomised, parallel group, superiority trial (ClinicalTrials.gov: NCT03069807) conducted in 34 general practices in London, UK, comparing LTBI treatment in recent migrants in primary care to secondary care. The primary outcome was treatment completion, defined as taking ≥90% of antibiotic doses. Secondary outcomes included treatment acceptance, adherence, adverse effects, patient satisfaction, TB incidence and a cost-effectiveness analysis. Analyses were performed on an intention-to-treat basis.

Results

Between September 2016 and May 2019, 362 recent migrants with LTBI were offered treatment and 276 accepted. Treatment completion was similar in primary and secondary care (82.6% versus 86.0%; adjusted OR (aOR) 0.64, 95% CI 0.31–1.29). There was no difference in drug-induced liver injury between primary and secondary care (0.7% versus 2.3%; aOR 0.29, 95% CI 0.03–2.84). Treatment acceptance was lower in primary care (65.2% (146/224) versus 94.2% (130/138); aOR 0.10, 95% CI 0.03–0.30). The estimated cost per patient completing treatment was lower in primary care, with an incremental saving of GBP 315.27 (95% CI 313.47–317.07).

Conclusions

The treatment of LTBI in recent migrants within primary care does not result in higher rates of treatment completion but is safe and costs less when compared to secondary care.




atm

Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors [Metabolism, Transport, and Pharmacogenetics]

Glioblastoma (GBM) is a disease of the whole brain, with infiltrative tumor cells protected by an intact blood-brain barrier (BBB). GBM has a poor prognosis despite aggressive treatment, in part due to the lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage. Subsequent activation of DNA damage response (DDR) pathways can induce resistance. Various DDR inhibitors, targeting the key regulators of these pathways such as ataxia telangiectasia mutated and Rad3-related (ATR), are being explored as radio- and chemosensitizers. Elimusertib, a novel ATR kinase inhibitor, can prevent repair of damaged DNA, increasing efficacy of DNA-damaging cytotoxic therapies. Robust synergy was observed in vitro when elimusertib was combined with the DNA-damaging agent temozolomide; however, we did not observe improvement with this combination in in vivo efficacy studies in GBM orthotopic tumor-bearing mice. This in vitro–in vivo disconnect was explored to understand factors influencing central nervous system (CNS) distribution of elimusertib and reasons for lack of efficacy. We observed that elimusertib is rapidly cleared from systemic circulation in mice and would not maintain adequate exposure in the CNS for efficacious combination therapy with temozolomide. CNS distribution of elimusertib is partially limited by P-glycoprotein efflux at the BBB, and high binding to CNS tissues leads to low levels of pharmacologically active (unbound) drug in the brain. Acknowledging the potential for interspecies differences in pharmacokinetics, these data suggest that clinical translation of elimusertib in combination with temozolomide for treatment of GBM may be limited.

SIGNIFICANCE STATEMENT

This study examined the disconnect between the in vitro synergy and in vivo efficacy of elimusertib/temozolomide combination therapy by exploring systemic and central nervous system (CNS) distributional pharmacokinetics. Results indicate that the lack of improvement in in vivo efficacy in glioblastoma (GBM) patient-derived xenograft (PDX) models could be attributed to inadequate exposure of pharmacologically active drug concentrations in the CNS. These observations can guide further exploration of elimusertib for the treatment of GBM or other CNS tumors.




atm

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair [Review Article]

Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS), with a putative autoimmune origin and complex pathogenesis. Modification of the natural history of MS by reducing relapses and slowing disability accumulation was first attained in the 1990 s with the development of the first-generation disease-modifying therapies. Glatiramer acetate (GA), a copolymer of L-alanine, L-lysine, L-glutamic acid, and L-tyrosine, was discovered due to its ability to suppress the animal model of MS, experimental autoimmune encephalomyelitis. Extensive clinical trials and long-term assessments established the efficacy and the safety of GA. Furthermore, studies of the therapeutic processes induced by GA in animal models and in MS patients indicate that GA affects various levels of the innate and the adaptive immune response, generating deviation from proinflammatory to anti-inflammatory pathways. This includes competition for binding to antigen presenting cells; driving dendritic cells, monocytes, and B-cells toward anti-inflammatory responses; and stimulating T-helper 2 and T-regulatory cells. The immune cells stimulated by GA reach the CNS and secrete in situ anti-inflammatory cytokines alleviating the pathological processes. Furthermore, cumulative findings reveal that in addition to its immunomodulatory effect, GA promotes neuroprotective repair processes such as neurotrophic factors secretion, remyelination, and neurogenesis. This review aims to provide an overview of MS pathology diagnosis and treatment as well as the diverse mechanism of action of GA.

Significance Statement

Understanding the complex MS immune pathogenesis provided multiple targets for therapeutic intervention, resulting in a plethora of agents, with various mechanisms of action, efficacy, and safety profiles. However, promoting repair beyond the body’s limited spontaneous extent is still a major challenge. GA, one of the first approved disease-modifying therapies, induces diverse immunomodulatory effects. Furthermore, GA treatment results in elevated neurotrophic factors secretion, remyelination and neurogenesis, supporting the notion that immunomodulatory treatment can support in situ a growth-promoting and repair environment.




atm

Rapid genome diagnosis of alveolar capillary dysplasia leading to treatment in a child with respiratory and cardiac failure [RESEARCH REPORT]

Alveolar capillary dysplasia (ACD) is a fatal disorder that typically presents in the neonatal period with refractory hypoxemia and pulmonary hypertension. Lung biopsy is traditionally required to establish the diagnosis. We report a 22-mo-old male who presented with anemia, severe pulmonary hypertension, and right heart failure. He had a complicated hospital course resulting in cardiac arrest and requirement for extracorporeal membrane oxygenation. Computed tomography of the chest showed a heterogenous pattern of interlobular septal thickening and pulmonary edema. The etiology of his condition was unknown, lung biopsy was contraindicated because of his medical fragility, and discussions were held to move to palliative care. Rapid whole-genome sequencing (rWGS) was performed. In 2 d it resulted, revealing a novel FOXF1 gene pathogenic variant that led to the presumptive diagnosis of atypical ACD. Cases of atypical ACD have been reported with survival in patients using medical therapy or lung transplantation. Based on the rWGS diagnosis and more favorable potential of atypical ACD, aggressive medical treatment was pursued. The patient was discharged home after 67 d in the hospital; he is currently doing well more than 30 mo after his initial presentation with only one subsequent hospitalization and no requirement for lung transplantation. Our case reveals the potential for use of rWGS in a critically ill child in which the diagnosis is unknown. rWGS and other advanced genetic tests can guide clinical management and expand our understanding of atypical ACD and other conditions.




atm

Stage III NSCLC treatment options: too many choices

Stage III nonsmall cell lung cancer (NSCLC) represents a wide range of tumour (T1 to T4) and nodal (N0 to N3) components, requiring variable management and a multidisciplinary approach. Recent advancements in minimally invasive techniques, molecular biology and novel drug discoveries have accelerated the refinement of stage III NSCLC management. The latest developments in staging include the forthcoming update of the nodal component in the 9th TNM (tumour–node–metastasis) edition, which emphasises the critical role for endobronchial ultrasonography in mediastinal staging. Recent treatment developments include the use of immunotherapy and targeted molecular therapy in both the neoadjuvant and adjuvant setting, either in combination with other modalities or used alone as consolidation. Surgical and radiotherapy advancements have further enhanced patient outcomes. These developments have significantly improved the prognosis for patients with stage III NSCLC. Fast-changing recommendations have also brought about a challenge, with clinicians facing a number of options to choose from. Therefore, a multimodal approach by a multidisciplinary team has become even more crucial in managing stage III NSCLC.




atm

Palliative care in lung cancer: tumour- and treatment-related complications in lung cancer and their management

Palliative care pertains to the holistic multidimensional concept of "patient-centred" care. It is an interprofessional specialty, primarily aiming to improve quality of care for cancer patients and their families, from the time of diagnosis of malignant disease, over the continuum of cancer care, and extending after the patient's death to the period of bereavement to support the patient's family. There are various complex and frequently unmet needs of lung cancer patients and their families/caregivers, not only physical but also psychological, social, spiritual and cultural. Systematic monitoring of patients’ symptoms using validated questionnaires and patient-reported outcomes (PROs), on a regular basis, is highly encouraged and recommended in recent guidelines on the role of PRO measures in the continuum of cancer clinical care. It improves patient–physician communication, physician awareness of symptoms, symptom control, patient satisfaction, health-related quality of life and cost-effectiveness. This implies that all treating physicians should improve their skills in communication with lung cancer patients/relatives and become more familiar with this multidimensional assessment, repeatedly screening patients for palliative care needs. Therefore, they should receive education and training to develop palliative care knowledge, skills and attitudes. This review is dedicated to lung cancer palliative care essentials that should be within the competences of treating physicians, i.e. pneumologists/thoracic oncologists.




atm

Cloud atlas of Mars reveals an atmosphere unlike our own

Using images captured by the European Space Agency’s Mars Express spacecraft, researchers have created a cloud atlas of Mars, to better understand the climate of the Red Planet




atm

Period atmosphere is best part of game set on turbulent oil rig

In Still Wakes the Deep, you play as a Glaswegian electrician on a 1970s oil rig. The well-crafted setting gives way to horror, but I wish I could linger in mundanity for longer, says Jacob Aron




atm

How deadly is mpox and what treatments are available?

When the fever, pains and pus-filled lesions of an mpox infection strike, how dangerous is it and how can it be treated?




atm

Lab-grown stem cells could be a 'breakthrough' for cancer treatment

Stem cells made in the lab may one day aid cancer treatment by reducing our reliance on donors




atm

Rejecting standard cancer treatment like Elle Macpherson is a big risk

People with cancer may have understandable reasons to follow Australian supermodel Elle Macpherson in declining chemotherapy, but the odds aren’t in their favour, warns Elle Hunt




atm

Can we finally reverse balding with these new experimental treatments?

Male pattern baldness could soon be a thing of the past, with new hair loss treatments beginning to show tantalising results




atm

MDMA was hyped as a promising treatment for PTSD – what went wrong?

For years, it seemed MDMA-assisted therapy would revolutionise PTSD treatment. But poor trial design and alleged misconduct ultimately stopped the treatment from receiving government approval




atm

Shivarajkumar opens up on his health: I am underdoing treatment

Kannada superstar Shivarajkumar, who is awaiting the release of his much-anticipated film ‘Bhairathi Ranagal’, has said that he is set to undergo a surgery for his illness




atm

Strictly pro isn’t happy with BBC show’s treatment of Shayne Ward

‘You deserve something better!’ Ward’s partner Nancy Xu said of result




atm

Oversimplification about integration of traditional & modern treatment systems creates confusion: Dr Kotecha

Oversimplification about integration of traditional and modern treatment systems often creates confusion among the stakeholders, and nobody understands the reality of the integration and what it is meant for, said Dr.




atm

Pharmacy negotiators in talks over plans to distribute COVID-19 treatments in primary care

The Pharmaceutical Services Negotiating Committee is in talks with the government over potential plans to distribute COVID-19 treatments in primary care.




atm

Extended Medicaid Coverage Would Help Postpartum Patients With Treatment for Opioid Use Disorder

Between 1999 and 2014, opioid use disorder (OUD) among pregnant women more than quadrupled, risking the health of the women—before and after giving birth—and their infants. As states grapple with COVID-19’s exacerbation of the opioid crisis, several are taking innovative steps to address the needs of high-risk groups, including low-income, postpartum patients with OUD.




atm

Expanding Treatment for Opioid Use Disorders

As the coronavirus pandemic grips the world, the opioid epidemic continues to affect millions of Americans. Several states are developing innovative ways to tackle this public health issue. In this episode, we speak with Beth Connolly, who leads Pew’s research on substance use disorders, and Louisiana Representative Paula Davis, who helped ensure effective treatment in her state.




atm

Primary Care Providers Can Help Steer People to Opioid Addiction Treatment

The United States is grappling with two severe health crises: the COVID-19 pandemic and an opioid epidemic that appears to be worsening as more people deal with stress and isolation as they face increased barriers to medical care. Preliminary numbers for 2020 show that overdose deaths were outpacing the record-setting number of more than 71,000 fatalities in 2019.




atm

Proposed law could mandate treatment for community disturbances linked to mental health

The Community Disputes Resolution Tribunals (CDRT) will be able to mandate mental health treatment for those who cause unreasonable interferences in the community if a bill to amend the Community Disputes Resolution Act (CDRA) goes through.  The bill was proposed in Parliament by Minister for Community, Culture and Youth Edwin Tong on Tuesday (Nov 12). The CDRT currently hears disputes under CDRA between neighbours involving acts of unreasonable interference with the enjoyment or use of places of residence. Under the bill, the tribunal will be able to issue Mandatory Treatment Orders (MTO) should there be a belief that the acts of disturbance stem from an underlying psychiatric condition. "In those cases, the issue therefore is not just a disamenity one," Minister Tong said. "Hence, the MTO is intended to address the root cause of certain acts that a resident may engage in." Tong added that their priority remains in persuading the resident to go for treatment voluntarily, and that the CDRT-issued MTO is a measure of last resort. There are also criteria that must be met for the MTO to be issued.





atm

Study finds changes in treatment have increased life span for childhood cancer survivors - Hear more from Dr. Armstrong

Hear more from Dr. Armstrong




atm

Abbott's iDesign System Creates 3-D Map of the Eye for Precise, Personalized LASIK Vision Treatment - NASA�s Newest Space Telescope is Calibrated by the Same Technology Used in LASIK

Years ago, NASA�s Hubble Space Telescope launched with an error in the telescope�s mirror, which blurred its images for its first years in orbit. For NASA�s upcoming James Webb Space Telescope that is traveling much farther out in space, there can�t be a mistake. Abbott scientists created a technology to calibrate the mirrors on NASA�s new James Webb Space Telescope, which is now the same technology used in the iDesign System that allows ophthalmologists to map the human eye with great precision for a highly personalized LASIK treatment.





atm

Gout & Uric Acid Education Society Hosts Roundtable Exploring Strategies for Elevating the Severity of Gout and Improving Access to Public Education and Treatment - Gout as a Serious Health Issue

Gout as a Serious Health Issue




atm

Man is left jobless when scorned ex-employee refuses to hire him after receiving the same treatment 9 months prior: ‘HE is now redundant’

Nothing feels worse than being "made redundant" at your company after spending years being the best employee you could be. You did everything right! An employee that was always on time, always got tasks done in a timely manner, and never caused a ruckus in the office. Sometimes, there's no rhyme or reason to being made redundant. It's not a reflection of your work ethic, but rather, the very DNA of the corporate machine. Churn in, churn out.

When you finally go to apply for another position, you're surprised to see one of your ex-colleagues at that specific company. Hoping this would work in your favor, you complete the interview with high hopes. Instead of putting in a good word about you, your ex-colleague decides to tell the interviewer that you had "asked too many questions" at your previous workplace. Isn't curiosity what most employers want? Well, 9 months later, you see someone very familiar waiting to be interviewed at your new company. Your mouth turns upward into a small when you realize it's the same ex-colleague who refused to hire you. Sweet karma.




atm

PROTAC: A Promising Path-Breaking Technology for Cancer Treatment

Highlights: Protein homeostasis is critical for physiology of cell and their functioning PROTACs have the abilit




atm

Parasite Found in Cat Poop Holds Key to Brain Disease Treatments

Highlights: Scientists found Toxoplasma gondii may help deliver therapeutic proteins to the brain, a breakthrou




atm

How Gender Disparities Impact Multiple Sclerosis Treatment for Women?

A groundbreaking study has unveiled a critical issue of therapeutic inertia in treating women with medlinkmultiple sclerosis/medlink (MS), underscoring